Note 3 - Intangible Assets

12 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

3.     

Intangible Assets

Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired (see footnote 2):

	June 30, 2015
	Weighted Average Amortization Period (in Years)		Gross Carrying Amount		Accumulated Amortization		Net
Trade names		7	$	30	$	6	$	24
Licenses		7		490		96		394
Customer relationships		3		449		206		243
Device registration		7		92		20		72
Covenants not to compete		5		955		263		692
Amortizable intangible assets				2,016		591		1,425
Clinical protocols				19,870		--		19,870
Total			$	21,886	$	591	$	21,295

	June 30, 2014
	Weighted Average Amortization Period (in Years)		Gross Carrying Amount		Accumulated Amortization		Net
Trade names		7	$	32	$	2	$	30
Licenses		7		550		29		521
Customer relationships		3		477		59		418
Device registration		7		218		12		206
Covenants not to compete		5		955		72		883
Amortizable intangible assets				2,232		174		2,058
Clinical protocols				19,870		--		19,870
Total			$	22,102	$	174	$	21,928

The change in the gross carrying amount is due to foreign currency exchange fluctuations and a $117 impairment in the third quarter of fiscal 2015, of the device registration and licenses intangible assets due to discontinuing a cord-blood product. Amortization of intangible assets was $458 and $174 for the years ended June 30, 2015 and 2014. Clinical protocols have not yet been introduced to the market place and are therefore not yet subject to amortization. The Company’s estimated future amortization expense for subsequent years ended June 30, as follows:

Year Ended June 30,
2016	$	448
2017		367
2018		273
2019		201
2020		83
Thereafter		53
Total	$	1,425